- Home
- SBFM vs DRRX Comparison
SBFM vs DRRX Comparison
Compare SBFM & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- DRRX
- Stock Information
- Founded
- SBFM 2006
- DRRX 1998
- Country
- SBFM United States
- DRRX United States
- Employees
- SBFM N/A
- DRRX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- DRRX Health Care
- Exchange
- SBFM Nasdaq
- DRRX Nasdaq
- Market Cap
- SBFM 4.9M
- DRRX N/A
- IPO Year
- SBFM N/A
- DRRX 2000
- Fundamental
- Price
- SBFM $1.55
- DRRX $0.70
- Analyst Decision
- SBFM Strong Buy
- DRRX Hold
- Analyst Count
- SBFM 1
- DRRX 1
- Target Price
- SBFM $15.00
- DRRX N/A
- AVG Volume (30 Days)
- SBFM 4.3M
- DRRX 54.0K
- Earning Date
- SBFM 05-19-2025
- DRRX 05-12-2025
- Dividend Yield
- SBFM N/A
- DRRX N/A
- EPS Growth
- SBFM N/A
- DRRX N/A
- EPS
- SBFM N/A
- DRRX N/A
- Revenue
- SBFM $34,874,283.00
- DRRX $2,031,000.00
- Revenue This Year
- SBFM $192.48
- DRRX N/A
- Revenue Next Year
- SBFM N/A
- DRRX $935.93
- P/E Ratio
- SBFM N/A
- DRRX N/A
- Revenue Growth
- SBFM 44.75
- DRRX N/A
- 52 Week Low
- SBFM $1.17
- DRRX $0.67
- 52 Week High
- SBFM $33.60
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- SBFM 44.81
- DRRX 37.40
- Support Level
- SBFM $1.17
- DRRX $0.67
- Resistance Level
- SBFM $1.59
- DRRX $0.75
- Average True Range (ATR)
- SBFM 0.19
- DRRX 0.05
- MACD
- SBFM 0.03
- DRRX -0.00
- Stochastic Oscillator
- SBFM 52.84
- DRRX 20.00
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.